Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8898803 | 0.92 | HIF1A (0.60) | HIF1AMRGPRX4 | |
| SCHEMBL9277223 | 0.90 | HIF1A (0.48) | HIF1AALDH1A1RXFP1MAOBLMNA | |
| SCHEMBL7525484 | 0.90 | HIF1A (0.48) | HIF1AALDH1A1RXFP1MAOBLMNA | |
| SCHEMBL9080938 | 0.88 | HIF1A (0.60) | HIF1AMAOBMRGPRX4 | |
| SCHEMBL8898206 | 0.88 | HIF1A (0.60) | HIF1AMAOBMRGPRX4 | |
| SCHEMBL9667323 | 0.88 | HIF1A (0.62) | HIF1APOLBMRGPRX4 | |
| SCHEMBL8896729 | 0.86 | HIF1A (0.60) | HIF1AMRGPRX4 | |
| Kresoxym-Methyl SCHEMBL12920836 | 0.85 | HIF1A (0.64) | HIF1AMAPT | |
| Kresoxim-Methyl SCHEMBL29356012 | 0.85 | HIF1A (0.64) | HIF1AMAPT | |
| Kresoxim-Methyl SCHEMBL18664 | 0.85 | HIF1A (0.64) | HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082303-A1 | Iminooxy-substituted benzyl phenyl ethers, processes and intermediates for their preparation, compositions comprising them, and their use for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-27 | — | — | US | disclosed |
| EP-1118609-A2 | Iminooxi-substituted benzyl phenyl ethers, process and intermediates for their preparation, agents containing them as well as their use in combatting harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082303-A1 | Iminooxy-substituted benzyl phenyl ethers, processes and intermediates for their preparation, compositions comprising them, and their use for controlling harmful fungi | CBR3, CFH, CNPY3 | HIF1A 830/4885ALDH1A1 2332/4885RXFP1 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.